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MaBACKGROUND For patients undergoing mitral valve (MV) repair, the indications for and results of concomitant
tricuspid annuloplasty remain controversial.
OBJECTIVES This study was designed to compare a strategy of routine concomitant tricuspid annuloplasty for mod-
erate tricuspid regurgitation (TR) or tricuspid annular dilation in patients undergoing degenerative MV surgery.
METHODS Of 645 consecutive patients (mean age 57  13 years) undergoing primary repair of degenerative mitral
regurgitation between 2003 and 2011, 419 (65%) underwent concomitant tricuspid annuloplasty for moderate TR and/or
tricuspid annular dilation. These patients were retrospectively analyzed with longitudinal echocardiographic follow-up.
RESULTS Patients undergoing tricuspid valve repair were older (mean age 59.2 years vs. 52.3 years), hadworse right and left
ventricular function and higher pulmonary artery pressures, and were more likely to have had atrial ﬁbrillation than patients
undergoing isolated MV repair (all p < 0.05). No signiﬁcant difference in 30-day mortality, morbidity, or permanent pace-
maker requirement was seen between treatment groups. Freedom frommoderate TR at 7 years was not signiﬁcantly different
in the 2 groups, butmultivariate analysis showed that tricuspid annuloplastywas independently associatedwith freedom from
late moderate TR (p ¼ 0.04), and was an independent predictor of recovery of right ventricular function (p ¼ 0.02).
CONCLUSIONS In patients with moderate TR or tricuspid annular dilation who were undergoing degenerative mitral
repair, concomitant tricuspid annuloplasty is safe, effective, and associated with improved long-term right-sided
remodeling. Routine treatment of moderate TR or tricuspid annular dilation at the time of MV repair appears to be
beneﬁcial. (J Am Coll Cardiol 2015;65:1931–8) © 2015 by the American College of Cardiology Foundation.F or patients with less than severe tricuspidregurgitation (TR) who are undergoing mitralvalve (MV) repair, the indications for concom-
itant tricuspid annuloplasty remain subject to debate,
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
MV = mitral valve
PAH = pulmonary artery
hypertension
RV = right ventricular
TR = tricuspid regurgitation
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1932outcome (7); and the safety and efﬁcacy of
tricuspid annuloplasty (11–13), particularly
compared with the relatively high mortality
associated with reoperative surgery for iso-
lated TR. Data on the effect of concomitant
tricuspid annuloplasty on progression of
TR, ventricular remodeling, and pulmonary
artery hypertension (PAH) after degenerative
MV repair are lacking.The aim of this study was to evaluate the outcomes
of a strategy of routine concomitant tricuspid annu-
loplasty for moderate TR or signiﬁcant annular dila-
tion in patients undergoing surgical treatment of a
degenerative MV.SEE PAGE 1939METHODS
STUDY POPULATION. We retrospectively analyzed
646 consecutive patients with mitral regurgitation sec-
ondary to degenerative disease who underwent MV
repair by a single surgeon (D.H.A.) atMount SinaiMedical
Center (New York, New York) between 2003 and 2011.
One patient underwent MV replacement after repair
complicated by atrioventricular groove hematoma: this
patientwas excluded from theanalysis. All other patients
underwent MV repair (99.8% repair rate). Patients with
severe 3-vessel coronary artery disease, and patients
who required concomitant aortic valve replacement or
reoperative surgery were excluded from the analysis,
to reduce the number of potential major confounders.
Degenerative MV disease was deﬁned as Carpentier type
II mitral regurgitation resulting from chordal elongation
or chordal rupture with excess leaﬂet motion. Barlow
disease was deﬁned by the presence of multisegment
prolapse in a large valve; ﬁbroelastic deﬁciency as the
presence of single segment prolapse in a normal-sized
valve; and forme fruste as valves sharing characteristics
of both these etiologic factors. Connective tissue disor-
ders were diagnosed pre-operatively on the basis of
established diagnostic criteria. The research protocol
was approved by the Icahn School of Medicine at Mount
Sinai Institutional Review Board and was compliant
with Health Insurance Portability and Accountability
Act regulations and the ethical guidelines of the 1975
Declaration of Helsinki. The approval included a waiver
of informed consent and a request to access data of
decedents.
Indications for tricuspid valve repair were as fol-
lows: 1) the presence of moderate TR on either the
pre-operative or the pre-bypass echocardiogram
(whichever was the greater grade); 2) signiﬁcant
annular dilation assessed on pre-bypass echocardi-
ography at end-diastolic diameter in the 4-chamberview as an annulus >40 mm; or 3) in the case of
equivocal ﬁndings, on the basis of direct assessment,
intraoperative saline testing, and comparison of the
anterior and posterior leaﬂet surface area with the
annulus size (14) (Online Figure 1).
Patients undergoing tricuspid annuloplasty (65%;
n ¼ 419) received ring sizes ranging from 24 to 34; 83%
of whom received a ring size of 28 or smaller. The
tricuspid valve was evaluated directly via a right
atriotomy for a mismatch between the leaﬂet surface
area and the annulus size, when echocardiographic
ﬁndings were equivocal and additional risk factors
were present (e.g., atrial ﬁbrillation [AF], PAH, or
right ventricular [RV] dysfunction), as found in 301
patients (47%). Of this group, 221 underwent tricus-
pid annuloplasty. Techniques of tricuspid valve and
MV repair have been previously described in detail
(14). The tricuspid ring was sized according to the
combined surface area of the posterior and anterior
tricuspid leaﬂets extended using a right-angle hook
and implanted with simple, interrupted mattress su-
tures sparing the septal annulus and conduction
tissue in the region of the apex of the triangle of Koch.
DATA COLLECTION AND FOLLOW-UP. Operative
mortality was deﬁned as any death within 30 days
or at any time during the same hospital stay. Post-
operative morbidity was deﬁned as stroke, new-
onset renal failure, ventilation or reintubation for
>72 h, new requirement for permanent pacemaker,
surgical re-exploration, and deep sternal wound
infection or sepsis. Pre-operative RV function was
assessed qualitatively, mainly on the basis of
wall motion abnormality and ventricular dilation
by echocardiography pre-operatively or, if that was
not available, by pre-bypass transesophageal echo-
cardiography. Mitral regurgitation and TR were
graded according to guideline-recommended stan-
dard quantitative and semiquantitative methods as
none, mild, moderate, or severe (15). Pre-operative
and pre-discharge echocardiography was obtained for
all patients, of whom 85% (n ¼ 535) also had post-
discharge echocardiography available. A total of
1,432 echocardiograms were included in the analysis.
Mean follow-up was 3.7 years (range 0.1 to 8.4 years).
The earliest echocardiogram on which moderate or
greater TR was indicated for each patient was used to
designate recurrent TR. Post-operative RV function
was deﬁned as normal or decreased on the basis of the
latest report available for each patient; mild, moder-
ate, or severe dysfunction was grouped as decreased
RV function. Survival data were obtained for all pa-
tients; for documented U.S. patients, this occurred by
cross matching each patient’s Social Security number
with the Web-based Social Security death index.
TABLE 1 Characteristics of Patients With Degenerative Disease
All Patients
(n ¼ 645)
Mitral Repair
(n ¼ 226)
Mitral and
Tricuspid Repair
(n ¼ 419)
p
Value
Patient characteristics
Age, yrs 57.0  13.2 52.3  13.5 59.2  12.3 <0.001
Female 236 (36.6) 93 (41.2) 143 (34.1) 0.077
Body surface area, m2 1.90  0.24 1.93  0.23 1.88  0.26 0.099
Hypertension 296 (45.9) 82 (36.3) 214 (51.1) <0.001
Hypercholesterolemia 166 (25.7) 53 (23.5) 113 (27.0) 0.330
Diabetes mellitus 20 (3.1) 10 (4.4) 10 (2.4) 0.154
Coronary artery disease 77 (11.9) 28 (12.4) 49 (11.7) 0.795
Renal failure 2 (0.3) 0 (0) 2 (0.5) 0.298
Stroke 16 (2.5) 2 (0.9) 14 (3.3) 0.056
Etiology of mitral regurgitation
Barlow disease 206 (31.9) 72 (31.9) 134 (32.0) 0.975
Forme fruste 137 (21.1) 49 (21.2) 88 (21.0) 0.944
Fibroelastic deﬁciency 299 (46.5) 104 (46.5) 195 (46.5) 0.985
Marfan syndrome 3 (0.5) 1 (0.4) 2 (0.5) 0.951
Echocardiographic parameters
LV ejection fraction 60.7  7.5 61.5  6.9 60.2  7.7 0.032
LV end-systolic diameter, mm 35.6  6.7 34.7  6.9 36.0  6.6 0.011
Pulmonary artery systolic
pressure, mm Hg
35.7  14.0 31.8  12.3 37.6  14.4 <0.001
Atrial ﬁbrillation 121 (18.8) 26 (11.5) 95 (22.7) <0.001
Right atrium area, cm2 18.8  6.4 16.2  3.6 20.4  7.2 <0.001
Tricuspid annulus
diameter, mm
37.8  5.8 35.4  5.5 38.8  5.6 <0.001
RV dysfunction 105 (16.3) 21 (9.3) 84 (20.0) <0.001
Tricuspid regurgitation grade
None or trace 133 (58.8) 128 (30.5)
Mild 93 (41.2) 219 (52.3)
Moderate 0 (0) 63 (15.0)
Severe 0 (0) 9 (2.1)
Surgical details
Concomitant surgery
Coronary artery
bypass grafts
59 (9.1) 22 (9.7) 37 (8.8) 0.704
Maze procedure 126 (19.5) 27 (11.9) 99 (23.6) <0.001
Values are mean  SD or n (%).
LV ¼ left ventricular; RV ¼ right ventricular.
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1933DATA ANALYSIS. Continuous variables are expressed
as mean  SD. Categorical variables are presented as
proportions. Differences between groups were eval-
uated using the chi-square test or Fisher exact test
for categorical variables and independent samples
Student t test or the Mann-Whitney U test for
continuous variables. Paired samples Student t test
was used to compare continuous variables with
different follow-up occasions. The cumulative prob-
ability of survival, recurrent TR (deﬁned as moderate
or greater), and RV recovery were each estimated
using the Kaplan-Meier method, and the predictors
for each event were identiﬁed using Cox proportional
hazards regression analysis. The proportional haz-
ards assumption was met in all models. The pre-
dictors of post-operative mortality and morbidity
were analyzed using logistic regression analysis. The
variables with p value <0.25 in univariate analysis
were entered into the ﬁnal multivariate model. Re-
sults are presented as hazard ratios (HRs) or odds
ratios (ORs) with corresponding 95% conﬁdence in-
tervals (CIs). All tests were 2-tailed. A p value <0.05
was considered to be statistically signiﬁcant. The
statistical analysis was performed using the Statistics
Package for Social Sciences Statistics for Windows,
version 19.0 (IBM Corporation, Armonk, New York).
RESULTS
Baseline patient characteristics and operative infor-
mation are summarized in Table 1. Patients undergo-
ing concomitant tricuspid repair tended to be older
(mean age 59.2 years [19 to 90 years] vs. 52.3 years
[16 to 84 years]), with worse baseline left ventricular
and RV function and higher pulmonary artery pres-
sures, and they were almost twice as likely to have a
history of AF compared with patients in the isolated
mitral valve group (all p < 0.05).
Overall operative mortality was 0.6% (n ¼ 3 [75, 79,
and 85 years of age] died in the hospital, and a fourth
patient died suddenly of unknown causes 2 weeks
post-discharge after an otherwise routine post-
operative course). Tricuspid annuloplasty was not
found to be associated with signiﬁcantly increased
operative mortality or morbidity in univariate anal-
ysis (p ¼ 0.49) or multivariate analysis (p ¼ 0.6).
Speciﬁcally, there was no signiﬁcant difference in
implantation rate of permanent pacemakers post-
operatively between the tricuspid annuloplasty group
(2.4%; n ¼ 10) and the control group (1.3%; n ¼ 3) in
either univariate analysis (p ¼ 0.56) or multivariate
analysis (p ¼ 0.62). Seven-year survival for the
tricuspid annuloplasty group was 91  5% versus
97  2% for the isolated mitral repair group (p ¼ 0.1).There were no reoperations for recurrent TR during
study follow-up.
Freedom from moderate TR at 7 years was 97  2%
in the tricuspid annuloplasty group compared with
91  3% in the control group (p ¼ 0.07) (Figure 1). In
subgroup analysis limited to the patients with
mild TR, freedom from moderate TR at 7 years was
signiﬁcantly better in the 219 patients who under-
went concomitant tricuspid annuloplasty (97  3%)
than in the 93 patients who did not (97  3% vs.
83  7%; p ¼ 0.004). In Cox proportional hazards
regression analysis, tricuspid valve annuloplasty was
shown to be an independent predictor of freedom
from moderate or greater TR (hazard ratio [HR]: 0.26;
95% conﬁdence interval [CI]: 0.07 to 0.94; p ¼ 0.04)
FIGURE 1 Freedom From Moderate or Greater TR
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Greater freedom from late moderate tricuspid regurgitation (TR)
was observed in patients who underwent mitral valve repair
(MVR) and tricuspid annuloplasty (red dotted line) compared
with those who underwent only mitral valve repair (blue solid
line). CI ¼ conﬁdence interval; HR ¼ hazard ratio;
TVR ¼ tricuspid valve repair.
TABLE 2
Age
Female
Hypertens
Diabetes m
Coronary
Etiology (
FF
FED
LV ejectio
LV end-sy
>40
Pulmonary
pres
Atrial ﬁbri
Tricuspid
Pre-opera
Tricuspid
CI ¼ conﬁd
TR ¼ tricusp
Chikwe et al. J A C C V O L . 6 5 , N O . 1 8 , 2 0 1 5
Concomitant Tricuspid Annuloplasty in Mitral Valve Repair M A Y 1 2 , 2 0 1 5 : 1 9 3 1 – 8
1934(Table 2). Clinically signiﬁcant tricuspid stenosis was
not observed: the mean post-operative transtricuspid
gradient was 2.0 mm Hg, and there was no signiﬁcant
difference between patients who received a ring size
of 28 or less (mean gradient 2.1 mm Hg) or those who
received a ring size greater than 28 (1.9 mm Hg)
(p ¼ 0.24). Type of annuloplasty ring had no signiﬁ-
cant inﬂuence on residual or recurrent TR.Determinants of Recurrent TR (Moderate or Greater)
Univariate Multivariate
p
Value HR
p
Value HR (95% CI)
0.03 1.06 0.01 1.09 (1.02–1.16)
0.31 1.76
ion 0.17 0.41 0.06
ellitus 0.08 6.87 0.12
artery disease 0.12 2.58 0.42
Barlow disease as reference)
0.42 2.24 0.99
0.07 4.23 0.26
n fraction <60% 0.91 1.07
stolic diameter
mm
0.22 0.28 0.26
artery systolic
sures >50 mm Hg
0.45 1.64
llation 0.98 1.02
annulus diameter 0.58 1.06
tive RV dysfunction 0.75 1.24
annuloplasty 0.08 0.345 0.04 0.26 (0.07–0.94)
ence interval; FED ¼ ﬁbroelastic deﬁciency; FF ¼ forme fruste; HR ¼ hazard ratio;
id regurgitation; other abbreviations as in Table 1.Overall freedom from greater than moderate mitral
regurgitation in all patients at 7 years was 96  2%
and was not different between the treatment groups
(p ¼ 0.2). Longitudinal changes in echocardiographic
estimates of mean pulmonary artery systolic pressure
and right atrium area, as well as the percentage of
patients with RV dysfunction, are shown in Figures 2
to 5. In all these parameters, the tricuspid annulo-
plasty group had worse baseline parameters (all p <
0.001). After tricuspid annuloplasty, pulmonary ar-
tery systolic pressure and right atrium area improved
signiﬁcantly by the time of pre-discharge echocardi-
ography (both p < 0.001). It continued to improve
during follow-up, so that at midterm follow-up there
was no signiﬁcant difference in these parameters
between the 2 groups (p ¼ 0.97 and 0.50, respec-
tively). RV dysfunction initially deteriorated post-
operatively in both groups (both p < 0.001). This
change was more marked in the tricuspid annulo-
plasty group, in whom the rate of post-operative RV
dysfunction before discharge was almost 70%. During
follow-up, however, recovery of RV function occurred
more rapidly in the tricuspid annuloplasty group, and
by 5 years post-operatively, the proportion of patients
with normal RV function was similar in both groups
(Figure 5). Tricuspid annuloplasty was the main in-
dependent positive predictor of late RV recovery in
the subgroup of patients with pre-discharge RV
dysfunction (HR: 1.4; 95% CI: 1.06 to 1.96; p ¼ 0.02)
(Table 3).FIGURE 2 Longitudinal Change in Pulmonary Artery
Systolic Pressure
40
30
20
25
35
Preop Predis <1 y 1-3 y 3-5 y
Sy
st
ol
ic
 P
ul
m
on
ar
y 
Ar
te
ry
Pr
es
su
re
 (m
m
 H
g)
P<0.001
P=0.97
Mitral only MVR+TVR
Patients who underwent concomitant tricuspid valve repair (TVR)
had signiﬁcantly higher pulmonary pressures pre-operatively
compared with patients who underwent only mitral valve
repair (MVR) (p < 0.001). In patients who underwent MVR
and tricuspid annuloplasty, pulmonary artery pressures improved
such that at midterm follow-up, pulmonary artery pressures were
as low as those in patients who underwent MVR only (p ¼ 0.97).
Predis ¼ predischarge; Preop ¼ pre-operative.
FIGURE 3 Longitudinal Change in Right Atrium Area
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Mitral only MVR+TVR
Patients who underwent concomitant tricuspid valve repair (TVR)
had signiﬁcantly larger right atria pre-operatively compared
with patients who underwent mitral valve repair (MVR) only
(p < 0.001). In patients who underwent MVR repair and tricuspid
annuloplasty, right atrial size decreased to the point that at
midterm follow-up, right atrial size was the same as in those
patients who underwent MVR only (p ¼ 0.50). Abbreviations as
in Figure 2.
FIGURE 5 Recovery of RV Function
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The percentage of patients who normalized right ventricular (RV)
function after surgical treatment is stratiﬁed by the presence of
concomitant tricuspid valve repair (TVR) (red dotted line) versus
mitral valve repair (MVR) only (blue solid line). Abbreviations as
in Figure 1.
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1935DISCUSSION
This study reveals that a strategy of routine repair of
moderate or greater TR or signiﬁcant annular dila-
tion, or both, at the time of MV repair in patients with
degenerative disease (Central Illustration) almost
eliminates residual and recurrent TR without
incremental risk. Importantly, tricuspid valve repair
achieved superior freedom from TR and improved RVFIGURE 4 Longitudinal Change in the Proportion of Patients
With RV Dysfunction
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Mitral only MVR+TVR
Right ventricular (RV) dysfunction initially deteriorated after
surgical treatment in patients who underwent mitral valve repair
(MVR) only, as well as in patients who underwent concomitant
tricuspid valve repair (TVR) (both p < 0.001). During follow-up,
recovery of RV function occurred in both groups, and by 5 years
post-operatively, the proportion of patients with normal RV
function was similar in both groups (p ¼ 0.45). Abbreviations as
in Figure 2.function and PAH in patients with worse baseline risk
factors, compared with MV repair only.
POST-OPERATIVE PROGRESSION OF TRICUSPID
REGURGITATION. Data on the post-operative course
and clinical sequelae of TR are conﬂicting (2,6,8,
11,12,16–22). The reason may be, in part, that most
previous studies reported on groups with heteroge-
neous mitral disease etiology or surgical management.
In a study that focused exclusively on patients with
degenerative disease who were undergoing isolatedTABLE 3 Determinants of RV Function Recovery During Follow-Up
Univariate Multivariate
p
Value HR
p
Value HR (95% CI)
Age 0.04 0.99 0.16
Female 0.49 0.91
Hypertension 0.94 0.99
Diabetes mellitus 0.97 0.98
Coronary artery disease 0.06 0.66 0.18
LV ejection fraction <60% 0.82 0.97
LV end-systolic
diameter >40 mm
0.85 0.97
Pulmonary artery systolic
pressure >50 mm Hg
0.27 0.82
Atrial ﬁbrillation 0.01 0.64 0.02 0.68 (0.50–0.95)
Tricuspid annulus diameter 0.09 0.98 0.22
Pre-operative RV dysfunction 0.10 0.76 0.43
Pre-operative tricuspid
regurgitation moderate
or more
0.43 0.86
Tricuspid annuloplasty 0.04 1.38 0.02 1.4 (1.06–1.96)
Abbreviations as in Tables 1 and 2.
CENTRAL ILLUSTRATION Role of Tricuspid Annuloplasty in Mitral Repair
Chikwe, J. et al. J Am Coll Cardiol. 2015; 65(18):1931–8.
The indications for and effectiveness of concomitant tricuspid annuloplasty in patients with less than severe tricuspid regurgitation who are undergoing mitral valve
repair remain under debate. Patients undergoing mitral valve repair who demonstrated the presence of moderate tricuspid regurgitation on either the pre-operative or
the pre-bypass echocardiogram had concomitant tricuspid annuloplasty. Those patients who did not have moderate tricuspid regurgitation underwent further
assessment of annular dilation to determine the appropriateness of concomitant tricuspid annuloplasty.
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1936MV repair, Yilmaz et al. (6) reported that after a small
decrease in TR in the immediate post-operative
period, mean TR grade subsequently increased, but
by less than a single grade of regurgitation over
5 years, to a mean grade of mild to moderate TR.
The investigators concluded that their ﬁndings justi-
ﬁed a conservative approach to concomitant tricuspid
valve repair; their own reported rate of concomitant
tricuspid annuloplasty was 7% for patients with
degenerative MV disease during the study period.
However, by reporting mean TR grade, these inves-
tigators understated the risk of post-operative pro-
gression of TR observed in their patients, almost
one-third of whom had either moderate or severe
TR by 5-year follow-up (compared with 16% pre-
operatively) (6). Notably, this high prevalence of pro-
gressive TR occurred even though the investigatorsexcluded from their study the patients most at risk of
progression of TR (e.g., patients with pulmonary dis-
ease, signiﬁcant RV dysfunction, or right-sided heart
failure). As such, their data offer valuable insight
into the high rate of progression of untreated TR in
patients with degenerative MV disease.
CLINICAL SIGNIFICANCE OF POST-OPERATIVE
TRICUSPID REGURGITATION. Moderate TR is not
benign. It appears to be a predictor of reduced sur-
vival independent of PAH or RV and left ventricular
dysfunction (10); additionally, it has been shown to
be an independent risk factor for decreased func-
tional outcome and survival after mitral repair (7).
Although it is possible that TR is simply a more sen-
sitive marker of RV dysfunction (which may be
underestimated by reliance on echocardiographic
assessment of RV contractility, particularly in the
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Routine
tricuspid annuloplasty at the time of MV repair in patients with
moderate tricuspid regurgitation or tricuspid annular dilatation
minimizes the long-term risk of developing TR and may enhance
long-term right-sided remodeling.
COMPETENCY IN PATIENT CARE: Routine treatment of
moderate TR or tricuspid annular dilation at the time of MV repair
appears to be beneﬁcial. Direct intraoperative evaluation of the
tricuspid annulus can be useful when echocardiographic ﬁndings
are equivocal.
TRANSLATIONAL OUTLOOK: Studies of larger numbers
of patients undergoing MV repair are necessary to establish
whether routine tricuspid valve annuloplasty improves
survival and reduces the likelihood of late tricuspid valve
reoperation.
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1937presence of tricuspid valve insufﬁciency), this may
not be the whole story. In a detailed quantitative
echocardiographic analysis of pre-operative patients
with a degenerative MV, a “synergistic relationship”
between TR and RV dysfunction was described (23).
Our ﬁndings are consistent with those of Desai et al.
(24), who reported sustained improvement in RV
function after MV surgery with concomitant tricuspid
repair. TR results in progressive abnormalities of right
atrial and ventricular structure and function, and this
ﬁnding may explain why our strategy, designed to
eliminate signiﬁcant TR, resulted in enhanced long-
term remodeling of both the right ventricle and the
right atrium in patients who had impaired baseline
characteristics.
Thus, the results of this investigation conﬁrm
current guideline recommendations for routine tri-
cuspid valve repair for mild, moderate, or greater
functional TR with tricuspid annular dilation at the
time of MV repair (25).
STUDY LIMITATIONS. This is an analysis of a relatively
large cohort of patients undergoing repair of a degen-
erative MV with comprehensive echocardiographic
follow-up, providing an insight into RV remodeling, TR
grade, and PAH. The main limitations of this study
stem from its retrospective nature. Although multi-
variate analysis was used to adjust for RV dysfunction
and PAH, among other variables, we could not account
for other potential confounders, such as intraoperative
myocardial protection or variation in the performance
and interpretation of echocardiograms performed
outside our institution. Speciﬁcally, because of the
lack of a consistently used standardized grading sys-
tem, RV function was classiﬁed as normal or decreased
on the basis of qualitative reports; we could not
quantify the degree of dysfunction or reliably distin-
guish among mild, moderate, or severe dysfunction—
all of which were therefore grouped together as
decreased function. Our study does not provide in-
formation on the functional sequelae of TR andwas not
designed to determine differences in long-term efﬁ-
cacy of the different annuloplasty techniques
employed. However, it does provide new evidence
supporting the beneﬁts of eliminating TR from pa-
tients undergoing repair of a degenerative MV.CONCLUSIONS
TR can be nearly eliminated by a strategy of routine
ring annuloplasty at the time of MV repair in patients
with moderate TR or tricuspid annular dilation,
without adverse clinical consequences and with evi-
dence of enhanced long-term right-sided remodeling.
Further, in patients with risk factors for post-
operative TR, such as AF, PAH, or RV dysfunction,
and equivocal echocardiographic ﬁndings, our data
support a strategy of direct intraoperative evalua-
tion of tricuspid annular dilation.
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